Navigation Links
Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer

- Dr. Sylvie Bouchard to Retire from Company -

LAVAL, QC, April 28 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that Claire Brulle, M.D. has been appointed Senior Vice-President and Chief Medical Officer of the Company. Incumbent Chief Medical Officer Dr. Sylvie Bouchard has retired from Labopharm Inc. to focus on her career practicing medicine.

"Dr. Brulle brings to Labopharm a proven track record in medical affairs and clinical development and an impressive portfolio of competencies ranging from global clinical development to medical support for commercial operations," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "With extensive experience interacting with regulatory agencies in both North America and Europe and specific expertise in the area of pain therapeutics, Dr. Brulle is a strong addition to our team as we pursue our objective of commercializing multiple large market opportunity drugs."

Dr. Brulle has more than 25 years experience in the medical profession, including more than 15 years experience in the pharmaceutical industry with Pfizer Inc. During her tenure at Pfizer, Dr. Brulle held a series of increasingly senior medical roles, including lead positions for the Pain and Arthritis Franchise. Dr. Brulle received her Medical Degree from the Universite de Paris and has completed International and Leadership Development Programs from INSEAD Institute and Harvard Business School, respectively.

Mr. Howard-Tripp continued, "Dr. Bouchard's expertise and diligence has been invaluable to Labopharm's success to date. On behalf of the Company and the Board of Directors, I would like to thank her for her very significant contribution to Labopharm and wish her well as a full-time practicing physician."

Dr. Bouchard will continue to be available to Labopharm to transition the role to Dr. Brulle and will act as a consultant to the Company going forward.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the outcomes of clinical trials, the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
2. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
3. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
4. Labopharm to host conference call Thursday, February 21, 2008 at 8:30 a.m. (ET)
5. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
6. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
7. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm Reports Results for Third Quarter Fiscal 2007
10. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
11. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
Post Your Comments:
(Date:10/13/2015)... ... 13, 2015 , ... Symposium Chairman, Dr. Rod J. Rohrich is pleased to ... be held March 2nd and 3rd, 2016. The annual meeting, along with the ... physicians from around the world. , Key topics at this year's event will include ...
(Date:10/13/2015)... ... 13, 2015 , ... Relay (, a technology company that ... significant contract that will provide its award-winning private messaging solution to Independence Blue ... success of its Relay program, IBX Wire™, which now has over 550,000 members ...
(Date:10/13/2015)... ... 13, 2015 , ... NavaFit Inc. today announced the launch of its NavaFit ... participate in local fitness & sporting events, and stay motivated. Users can ... costs drive us to get more serious about fitness and wellness, individuals are constantly ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Protein is ... the body, including muscle, bone, and blood. But how much protein does the average ... than it might seem, according to the October 2015 issue of Harvard Men's ...
(Date:10/13/2015)... ... 2015 , ... Scientists in Seattle and Vancouver compared the diagnostic value of ... mesothelioma. Surviving Mesothelioma has just posted an article on the new research. Click ... and the University of British Columbia found that certain genetic alterations were seen just ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... EDISON, N.J. , Oct. 13, 2015 /PRNewswire/ ... or the "Company"), a biopharmaceutical company focused on ... today announced the closing of its previously announced ... common stock and warrants to purchase up to ... a fixed combined price to the public of ...
(Date:10/13/2015)... 2015  Human Longevity, Inc. (HLI), the genomics-based, technology-driven ... today the launch of the company,s first Health Nucleus, ... potential to transform healthcare. The inaugural Health Nucleus is ... at HLI,s headquarters facility. More Health Nucleus facilities are ... International cities. --> ...
(Date:10/13/2015)... 2015  Measurement in accountable care programs is ... incentives, but gaps in measurement can result in ... systems. A new, peer-reviewed study published in ... explores measurement gaps for high-priority conditions and ... --> --> "These gaps ...
Breaking Medicine Technology: